Skip to navigation Skip to main contented Skip to close file
TipRanks
Wed, January 14, 2026 astatine 8:16 AM CST
Leerink lowered the firm’s price target connected Kura Oncology (KURA) to $20 from $25 and keeps an Outperform standing connected the shares up of the company’s Q4 net report. Model updates instrumentality into relationship the preliminary Q4 fiscal results, including Komzifti nett merchandise gross and collaboration revenue, arsenic good arsenic 2026 fiscal guidance, Leerink adds.
Claim 70% Off TipRanks Premium
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See the apical stocks recommended by analysts >>
Read More connected KURA:
Disclaimer & DisclosureReport an Issue
-
3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts
-
Kura Oncology reports inducement grants nether Nasdaq listing rule
-
Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating
-
Positive Outlook for Kura Oncology Driven by Promising Clinical Trials and Strategic Advancements
-
Kura Oncology, Kyowa Kirin study operation information for KOMZIFTI with ven/aza

3 days ago
3



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·